Amgen, Inc. (NASDAQ:AMGN) – Stock analysts at William Blair upped their Q1 2018 earnings per share (EPS) estimates for Amgen in a report issued on Monday. William Blair analyst M. Phipps now expects that the medical research company will earn $3.34 per share for the quarter, up from their previous forecast of $3.33. William Blair also issued estimates for Amgen’s Q2 2018 earnings at $3.53 EPS, Q3 2018 earnings at $3.50 EPS, FY2018 earnings at $13.51 EPS, Q1 2019 earnings at $3.48 EPS, Q2 2019 earnings at $3.56 EPS, Q3 2019 earnings at $3.58 EPS, Q4 2019 earnings at $3.48 EPS and FY2019 earnings at $14.10 EPS.
A number of other equities analysts have also commented on the stock. Vetr lowered shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 price target on the stock. in a report on Tuesday, March 6th. Mizuho lifted their price target on shares of Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target on the stock. in a report on Monday, February 5th. JPMorgan Chase & Co. reiterated a “hold” rating and set a $191.00 price target on shares of Amgen in a report on Sunday, February 4th. Finally, Leerink Swann reiterated a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the company’s stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $191.72.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. Amgen’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.89 EPS.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 2.79%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 205.45%.
Amgen announced that its board has approved a stock repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.19% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Baker Ellis Asset Management LLC bought a new stake in shares of Amgen during the third quarter worth about $108,000. Phocas Financial Corp. bought a new stake in shares of Amgen during the second quarter worth about $110,000. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Amgen by 110.7% during the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock worth $113,000 after acquiring an additional 340 shares in the last quarter. Finally, Omnia Family Wealth LLC increased its position in shares of Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares in the last quarter. 79.61% of the stock is owned by hedge funds and other institutional investors.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.